Incyte

7 FDA Decisions You Can't Afford to Ignore in Q4
Motley Fool
Sat, 10/15/11 - 11:39 am
Bristol-Myers Squibb
Dapagliflozin
BioSante
Bio-T-Gel
Regeneron
Eylea
Transcept
Intermezzo
Incyte
ruxolitinib
Antares
Anturol
Top Mid- And Large-Cap Biotech Picks By Legendary Fund Managers
Seeking Alpha
Fri, 10/14/11 - 11:41 am
Alexion
Amgen
Amylin
Biogen Idec
Biomarin
Celgene
Gilead
Human Genome Sciences
Incyte
ONYX Pharmaceuticals
Seattle Genetics
Vertex
Theravance
8 Underperforming Biotech Stocks Being Bought by the Smart Money
Seeking Alpha
Sun, 09/25/11 - 12:55 pm
Amyris
NPS Pharmaceuticals
Targacept
Sequenom
Cadence Pharmaceuticals
Enzon
Dendreon
Incyte
The Big Bet on YM BioSciences
Motley Fool
Thu, 09/1/11 - 12:14 pm
YM BioSciences
myelofibrosis
ruxolitinib
CYT387
Novartis
Incyte
Biotech Calendar: 2011-12 FDA Drug Approvals
TheStreet.com
Thu, 08/11/11 - 12:37 pm
biotech
drug approvals
FDA
Eyelea
Regeneron
Dendreon
Provenge
NuPathe
Zelrix
Adcetris
Seattle Genetics
Soliris
Alexion
Dapagliflozin
AstraZeneca
Bristol-Myers Squibb
EXPAREL
Pacira
Roche
Zelboraf
Iluvien
Alimera
Bio-T-Gel
Teva Pharmaceuticals
BioSante
Zevalin
Spectrum
ruxolitinib
Incyte
Novartis
Pfizer
crizotinib
Antares
Anturol
Bydureon
Amlyin
Eli Lilly
Alkermes
AZ-004
Alexza
Corlux
Corcept Therapeutics
Affymax
Takeda
peginesatide
Levadex
MAP Pharmaceuticals
More Hot Biotech Trades for Second Half 2011
TheStreet.com
Tue, 07/12/11 - 10:27 am
Targacept
Aveo Pharmaceutical
Threshold Pharmaceuticals
Raptor Pharmaceuticals
Vertex Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
NuPathe
Pharmasset
Incyte
Adventrx
Celsion
Alimera
GTx
Ariad Pharmaceuticals
7 Rallying Biotech Stocks With Conservative Accounting Practices
Seeking Alpha
Fri, 07/1/11 - 09:56 am
Acorda Therapeutics
Incyte
Chelsea Therapeutics
Regeneron
Spectrum Pharmaceuticals
Jazz Pharmaceuticals
Neurocrine
3 Biotech Drugs With Promising Phase III Data, Moving Into FDA Review
Motley Fool
Fri, 07/1/11 - 09:44 am
FDA
Bristol-Myers Squibb
AstraZeneca
Pfizer
Incyte
Novartis
ruxolitinib
Apixaban
Dapagliflozin
Risk-Reward Balanced at Incyte
Yahoo/Zacks.com
Wed, 06/15/11 - 09:26 pm
Incyte
Eli Lilly
Novartis
Incyte Reports Additional Analyses of Symptomatic Improvement and Quality of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from the COMFORT-I Study
BusinessWire
Sun, 06/12/11 - 10:36 am
Incyte
ruxolitinib
myelofibrosis
A Dull ASCO And The Usual Sell-Off
Investopedia
Tue, 06/7/11 - 07:34 pm
ASCO
Celgene
Bristol-Myers Squibb
Incyte
Exelixis
Novartis
YM BioSciences
Neoprobe
With promising Ph3 data in hand, Incyte files for myelofibrosis drug OK
Fierce Biotech
Mon, 06/6/11 - 12:31 pm
Incyte
myelofibrosis
ruxolitinib
Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
Yahoo/BusinessWire
Sun, 06/5/11 - 10:03 am
Incyte
ruxolitinib
INC424
myelofibrosis
Novartis to showcase blockbuster cancer drug strategy at ASCO
Fierce Biotech
Wed, 06/1/11 - 06:44 pm
Novartis
ASCO
JAK inhibitors
Incyte
Incyte and YM Biosciences in Race to Market Strongest JAK Inhibitor
Seeking Alpha
Thu, 04/21/11 - 11:46 am
JAK inhibitors
YM BioSciences
Incyte
myelofibrosis
Top 15 Most Undervalued Biotech Stocks By Analyst Target Price
Seeking Alpha
Sat, 04/9/11 - 11:02 am
Prolor
Lexicon Pharmaceuticals
Dendreon
Human Genome Sciences
Targacept
Sequenom
Cadence Pharmaceuticals
Savient
ONYX Pharmaceuticals
Amylin
Emergent BioSolutions
XenoPort
Spectrum Pharmaceuticals
Incyte
Amgen
Cancer Drug Stocks to Trade Ahead of ASCO
TheStreet.com
Tue, 03/22/11 - 10:03 am
ASCO
Medivation
Exelixis
Dendreon
Bristol-Myers Squibb
Roche
Curis
Celgene
Sanofi
Ariad Pharmaceuticals
Merck
Incyte
Novartis
YM BioSciences
Pfizer
Aveo Pharmaceutical
ONYX Pharmaceuticals
Amgen
Synta
Vical
Oxigene
Cell Therapeutics
Oncothyreon
Novartis maps out a blockbuster future for INC424
Fierce Biotech
Wed, 03/16/11 - 09:21 am
Novartis
INC424
Incyte
JAK inhibitors
ruxolitinib
myelofibrosis
Incyte cancer drug meets goal in Europe study
Yahoo/AP
Tue, 03/15/11 - 10:03 am
Incyte
Europe
ruxolitinib
Novartis
5 Breakthrough Drugs for 2011
Barron's
Thu, 02/3/11 - 10:06 am
Benlysta
Human Genome Sciences
GSK
ipilimumab
Bristol-Myers Squibb
Vertex Pharmaceuticals
JNJ
Telaprevir
Novartis
Incyte
INCB-18424
Xarelto
Bayer

Pages